January 5, 2016January 6, 2016

LARIAT Clinical Trial Opens to Pulmonary Hypertension Patients with ILD

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company based in Irving, Texas, recently announced that it has enrolled the first patient with pulmonary hypertension associated with interstitial lung disease (PH-ILD) in ... Read more

September 16, 2015November 5, 2015

Reata Announces Presentation of Initial Phase 2 Data on Bardoxolone Methyl for PAH at 2015 CHEST Meeting

News, Pulmonary Hypertension

Irving, Texas-based Reata Pharmaceuticals, Inc, recently announced that it will present initial data evaluating bardoxolone methyl in patients with pulmonary arterial hypertension (PAH) who are on stable background therapy during the 2015 ... Read more